Kuan-Der Lee, MD PhD

Hematology and Oncology

SPECIALTY/PRACTICE AREAS：
• Medical Oncology
• Hematology
• Bone Marrow
• Peripheral Blood
• Stem Cell Transplantation
LANGUAGES SPOKEN：
• English
• Chinese

 

PROFESSIONAL EDUCATION：

• M.D., National Yang-Ming University, School of Medicine, Taipei, Taiwan
• Ph.D., University of Maryland, School of Medicine, Baltimore, Maryland, U.S.A. (1991~1996)
• Resident, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei (1996~1999)
• Clinical Fellow in Medical Oncology, Taipei Veterans General Hospital and National Health Research Institute Joint Program (1999~2001)
• Clinical Fellow in Hematology, Taipei Veterans General Hospital (2001~2002)

 

ADMINSTRATIVE APPOINTMENTS：

• Deputy Superintendent, Taipei Medical University Hospital (2017 April~now)
• Director, Department of Hematology and Oncology, Taipei Medical University Hospital (2018 August ~)
• Professor, Taipei Medical University School of Medicine (2017, in process)
• Deputy Superintendent, Chang Gung Memorial Hospital, Chiayi (2012~2017)
• Professor, Chang Gung University School of Medicine, Taiwan (2013~2017)
• Director, Department of Medicine, Chang-Gung Memorial Hospital, Chiayi (2009 ~2012)
• Director, Cancer Center, Chang-Gung Memorial Hospital, Chiayi (2006~2009)
• Chief, Division of Hematology and Oncology, Chang-Gung Memorial Hospital, Chiayi (2005~2009)

 

PUBLICATIONS：

• Kuan FC, Lai CH, Ku HY, Wu CF, Hsieh MC, Liu TW, Yeh CY and *Lee KD. The Survival Impact of Delayed Surgery and Adjuvant Chemotherapy on Stage II/III Rectal Cancer with Pathological Complete Response after Neoadjuvant Chemoradiation. Int J Cancer. 2017 Apr 1;140(7):1662-1669 (IF 5.53)
• Chen MF, Chen PT, Chen WC, Lu MS, Lin PY and *Lee KD. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget. 2016 Feb 16;7(7):7913-24. (IF 5.008)
• Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D and *Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British J Cancer, 2015 Nov 17;113(10):1519-28 (IF 5.569)
• *Lee KD, Chen CY, Huang HJ, Wang TY, Teng D, Huang SH, Lai CH and Chen MC. Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period. BMC Cancer. 2015 May 11;15:393. (IF 3.265)
• *Lee KD, Chen HH, Wang HM, Tsao CJ, Hsu TC, Chiu CF, Su WC, Wang JY. An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan. Oncology 2013 March;84(5):299-304. (IF 2.152)
• *Lee KD, Pai MY, Hsu CC, Chen CC, Chen YL, Chu PY, Lee CH, Chen LT, Chang JY, Huang TH, Hsiao SH, Leu YW. Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. Biochem Biophys Res Commun. 2012 Jun 15;422(4):578-85.(IF 2.371)
• Chen MF, Lu MS, Chen PT, Chen WC, Lin PY and *Lee KD. Role of interleukin 1 beta in esophageal squamous cell carcinoma. J Mol Med (Berl). 2012 Jan;90(1):89-100 (IF 4.855)